Monitoring and Managing Cardiovascular Risk in Immune Mediated Inflammatory Diseases

References

• Pincus T, Gibson KA, Block JA. Premature mortality: a neglected outcome in rheumatic diseases? Arthritis Care Res. 2015;67:1043–1046. doi:10.1002/acr.22554
   Web of Science ®Google Scholar
• Lerang K, Gilboe I-M, Steinar Thelle D, Gran JT. Mortality and years of potential life loss in systemic lupus erythematosus: a population-based cohort study. Lupus. 2014;23:1546–1552. doi:10.1177/0961203314551083
   PubMed Web of Science ®Google Scholar
• Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. AnnRheum Dis. 2012;71:1524–1529. doi:10.1136/annrheumdis-2011-200726
   PubMed Web of Science ®Google Scholar
• Bartels CM, Buhr KA, Goldberg JW, et al. Mortality and cardiovascular burden of systemic lupus erythematosus in a US population-based cohort. J Rheumatol. 2014;41:680–687. doi:10.3899/jrheum.130874
   PubMed Web of Science ®Google Scholar
• Jeganathan N, Nguyen E, Sathananthan M. Rheumatoid arthritis and associated-interstitial lung disease: mortality rates and trends. Ann Am Thorac Soc. 2021. doi:10.1513/AnnalsATS.202102-115OC
   PubMed Web of Science ®Google Scholar
• Atienza-Mateo B, Remuzgo-Martínez S, Mora Cuesta VM, et al. The spectrum of interstitial lung disease associated with autoimmune diseases: data of a 3.6-year prospective study from a referral center of interstitial lung disease and lung transplantation. J Clin Med. 2020;9:1606. doi:10.3390/jcm9061606
   PubMed Web of Science ®Google Scholar
• Lee KS, Kronbichler A, Eisenhut M, Lee KH, Shin J. Cardiovascular involvement in systemic rheumatic diseases: an integrated view for the treating physicians. Autoimmun Rev. 2018;17:201–214. doi:10.1016/j.autrev.2017.12.001
   PubMed Web of Science ®Google Scholar
• Nurmohamed MT, Heslinga M, Kitas GD. Cardiovascular comorbidity in rheumatic diseases. Nat Rev Rheumatol. 2015;11:693–704. doi:10.1038/nrrheum.2015.112
   PubMed Web of Science ®Google Scholar
• Psarras A, Soulaidopoulos S, Garyfallos A, Kitas G, Dimitroulas T. A critical view on cardiovascular risk in systemic sclerosis. Rheumatol Int. 2017;37:85–95. doi:10.1007/s00296-016-3530-3
   PubMed Web of Science ®Google Scholar
• Bacons PA, Kitas GD. The significance of vascular inflammation in rheumatoid arthritis. Ann Rheum Dis. 1994;53:621–623. doi:10.1136/ard.53.10.621
   PubMed Web of Science ®Google Scholar
• Semb AG, Rollefstad S, Provan SA, et al. Carotid plaque characteristics and disease activity in rheumatoid arthritis. J Rheumatol. 2013;40:359–368. doi:10.3899/jrheum.120621
   PubMed Web of Science ®Google Scholar
• Panoulas VF, Metsios GS, Pace AV, et al. Hypertension in rheumatoid arthritis. Rheumatology. 2008;47:1286–1298. doi:10.1093/rheumatology/ken159
   PubMed Web of Science ®Google Scholar
• Toms E, Symmons D, Kitas G. Dyslipidaemia in rheumatoid arthritis: the role of inflammation, drugs, lifestyle and genetic factors. Curr Vasc Pharmacol. 2010;8:301–326. doi:10.2174/157016110791112269
   PubMed Web of Science ®Google Scholar
• Stavropoulos-Kalinoglou A, Metsios GS, Koutedakis Y, Kitas GD; Antonios Stavropoulos-Kalinoglou GSMYKGDKitas. Body-size phenotypes and cardiometabolic risk in rheumatoid arthritis (short title: subgroups of obesity in RA). Mediterr J Rheumatol. 2016;27:48–54. doi:10.31138/mjr.27.2.48
   Google Scholar
• O’Brien C, Duda J, Kitas G, van Zanten J, Metsios G, Fenton S. Correlates of sedentary behaviour and light physical activity in people living with rheumatoid arthritis: protocol for a longitudinal study. Mediterr J Mediterr J Rheumatol. 2018;29:106–117. doi:10.31138/mjr.29.2.106
   PubMedGoogle Scholar
• Soehnlein O, Libby P, Zimmerman Z, Outterson K. Targeting inflammation in atherosclerosis — from experimental insights to the clinic. Nat Rev Drug Discov. 2021;20:1–22. doi:10.1038/d41573-020-00185-y
   PubMed Web of Science ®Google Scholar
• Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017;76:17–28. doi:10.1136/annrheumdis-2016-209775
   PubMed Web of Science ®Google Scholar
• Semb AG, Ikdahl E, Wibetoe G, Crowson C, Rollefstad S. Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis. Nat Rev Rheumatol. 2020;16:361–379. doi:10.1038/s41584-020-0428-y
   PubMed Web of Science ®Google Scholar
• Fragoulis GE, Soulaidopoulos S, Sfikakis PP, Dimitroulas T, Kitas GD. Effect of biologics on cardiovascular inflammation: mechanistic insights and risk reduction. J Inflamm Res. 2021;14:1915–1931. doi:10.2147/JIR.S282691
   PubMed Web of Science ®Google Scholar
• Yuri Gasparyan A, Ayvazyan L, Cocco G, Kitas D. Adverse cardiovascular effects of antirheumatic drugs: implications for clinical practice and research. Curr Pharm Des. 2012;18:1543–1555. doi:10.2174/138161212799504759
   PubMed Web of Science ®Google Scholar
• Roifman I, Beck PL, Anderson TJ, Eisenberg MJ, Genest J. Chronic inflammatory diseases and cardiovascular risk: a systematic review. Can J Cardiol. 2011;27:174–182. doi:10.1016/j.cjca.2010.12.040
   PubMed Web of Science ®Google Scholar
• Bacon PA, Stevens RJ, Carruthers DM, Young SP, Kitas GD. Accelerated atherogenesis in autoimmune rheumatic diseases. Autoimmun Rev. 2002;1:338–347. doi:10.1016/S1568-9972(02)00100-3
   PubMedGoogle Scholar
• Anyfanti P, Gavriilaki E, Douma S, Gkaliagkousi E. Endothelial dysfunction in patients with rheumatoid arthritis: the role of hypertension. Curr Hypertens Rep. 2020;22. doi:10.1007/s11906-020-01064-y
   Web of Science ®Google Scholar
• Anyfanti P, Gkaliagkousi E, Gavriilaki E, et al. Association of galectin‐3 with markers of myocardial function, atherosclerosis, and vascular fibrosis in patients with rheumatoid arthritis. Clin Cardiol. 2019;42:62–68. doi:10.1002/clc.23105
   PubMed Web of Science ®Google Scholar
• Dimitroulas T, Hodson J, Sandoo A, Smith J, Kitas GD. Endothelial injury in rheumatoid arthritis: a crosstalk between dimethylarginines and systemic inflammation. Arthritis Res Ther. 2017;19:32.
   PubMed Web of Science ®Google Scholar
• Sandoo A, Dimitroulas T, Hodson J, Smith JP, Douglas KM, Kitas GD. Cumulative inflammation associates with asymmetric dimethylarginine in rheumatoid arthritis: a 6 year follow-up study. Rheumatology. 2015;54:1145–1152. doi:10.1093/rheumatology/keu349
   PubMed Web of Science ®Google Scholar
• Anyfanti P, Triantafyllou A, Gkaliagkousi E, et al. Subendocardial viability ratio in patients with rheumatoid arthritis: comparison with healthy controls and identification of prognostic factors. Clin Rheumatol. 2017;36:1229–1236. doi:10.1007/s10067-017-3659-9
   PubMed Web of Science ®Google Scholar
• Anyfanti P, Triantafyllou A, Gkaliagkousi E, et al. Retinal vessel morphology in rheumatoid arthritis: association with systemic inflammation, subclinical atherosclerosis, and cardiovascular risk. Microcirculation. 2017;24:e12417. doi:10.1111/micc.12417
   Web of Science ®Google Scholar
• Anyfanti P, Gkaliagkousi E, Triantafyllou A, et al. Dermal capillary rarefaction as a marker of microvascular damage in patients with rheumatoid arthritis: association with inflammation and disorders of the macrocirculation. Microcirculation. 2018;25:e12451. doi:10.1111/micc.12451
   PubMed Web of Science ®Google Scholar
• Arida A, Protogerou A, Kitas G, Sfikakis P. Systemic inflammatory response and atherosclerosis: the paradigm of chronic inflammatory rheumatic diseases. Int J Mol Sci. 2018;19:1890. doi:10.3390/ijms19071890
   PubMed Web of Science ®Google Scholar
• Kitas GD, Dimitroulas T. Cardiovascular comorbidity in rheumatic and musculoskeletal diseases: where we are and how can we move forward. Int J Rheum Dis. 2021;24:473–476. doi:10.1111/1756-185X.14112
   PubMed Web of Science ®Google Scholar
• Conroy R. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987–1003. doi:10.1016/S0195-668X(03)00114-3
   PubMed Web of Science ®Google Scholar
• D’Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care. Circulation. 2008;117:743–753. doi:10.1161/CIRCULATIONAHA.107.699579
   PubMed Web of Science ®Google Scholar
• Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk. J Am Coll Cardiol. 2014;63:2935–2959. doi:10.1016/j.jacc.2013.11.005
   PubMed Web of Science ®Google Scholar
• Crowson CS, Rollefstad S, Kitas GD, van Riel PL, Gabriel SE, Semb AG. Challenges of developing a cardiovascular risk calculator for patients with rheumatoid arthritis. Arthritis Rheumatol. 2017;67:1995–2003. doi:10.1371/journal.pone.0174656
   Google Scholar
• Crowson CS, Gabriel SE, Semb AG, et al. Rheumatoid arthritis-specific cardiovascular risk scores are not superior to general risk scores: a validation analysis of patients from seven countries. Rheumatology. 2017;56:1102–1110. doi:10.1093/rheumatology/kex038
   PubMed Web of Science ®Google Scholar
• Wahlin B, Innala L, Magnusson S, et al. Performance of the expanded cardiovascular risk prediction score for rheumatoid arthritis is not superior to the ACC/AHA risk calculator. J Rheumatol. 2019;46:130–137. doi:10.3899/jrheum.171008
   PubMed Web of Science ®Google Scholar
• Drosos GC, Konstantonis G, Sfikakis PP, Tektonidou MG. Underperformance of clinical risk scores in identifying vascular ultrasound-based high cardiovascular risk in systemic lupus erythematosus. Eur J Prev Cardiol. 2021;28:346–352. doi:10.1093/eurjpc/zwaa256
   PubMed Web of Science ®Google Scholar
• Shen J, Lam SH, Shang Q, et al. Underestimation of risk of carotid subclinical atherosclerosis by cardiovascular risk scores in patients with psoriatic arthritis. J Rheumatol. 2018;45:218–226. doi:10.3899/jrheum.170025
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ. 2007;335:136. doi:10.1136/bmj.39261.471806.55
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ. 2008;336:1475–1482. doi:10.1136/bmj.39609.449676.25
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017;357:j2099.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women. JAMA. 2007;297:611–619. doi:10.1001/jama.297.6.611
   PubMed Web of Science ®Google Scholar
• Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global cardiovascular risk prediction. Circulation. 2008;118:2243–2251. doi:10.1161/CIRCULATIONAHA.108.814251
   PubMed Web of Science ®Google Scholar
• Solomon DH, Greenberg J, Curtis JR, et al. Derivation and internal validation of an expanded cardiovascular risk prediction score for rheumatoid arthritis: a consortium of rheumatology researchers of North America registry study. Arthritis Rheumatol. 2015;67:1995–2003. doi:10.1002/art.39195
   PubMed Web of Science ®Google Scholar
• Crowson CS, Matteson EL, Roger VL, Therneau TM, Gabriel SE. Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis. Am J Cardiol. 2012;110:420–424. doi:10.1016/j.amjcard.2012.03.044
   PubMed Web of Science ®Google Scholar
• Alemao E, Cawston H, Bourhis F, et al. Comparison of cardiovascular risk algorithms in patients with vs without rheumatoid arthritis and the role of C-reactive protein in predicting cardiovascular outcomes in rheumatoid arthritis. Rheumatology. 2017;56:777–786. doi:10.1093/rheumatology/kew440
   PubMed Web of Science ®Google Scholar
• Navarini L, Margiotta DPE, Caso F, et al. Performances of five risk algorithms in predicting cardiovascular events in patients with Psoriatic Arthritis: an Italian bicentric study. Ann Rheum Dis. 2018;77:1034. doi:10.1371/journal.pone.0205506
   Google Scholar
• Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. J Hypertens. 2018;36:1953–2041. doi:10.1097/HJH.0000000000001940
   PubMed Web of Science ®Google Scholar
• Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016;37:2315–2381. doi:10.1093/eurheartj/ehw106
   PubMed Web of Science ®Google Scholar
• Hansen PR, Feineis M, Abdulla J. Rheumatoid arthritis patients have higher prevalence and burden of asymptomatic coronary artery disease assessed by coronary computed tomography: a systematic literature review and meta-analysis. Eur J Intern Med. 2019;62:72–79. doi:10.1016/j.ejim.2019.02.018
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–188. doi:10.1093/eurheartj/ehz455
   PubMed Web of Science ®Google Scholar
• O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med. 1999;340:14–22. doi:10.1056/NEJM199901073400103
   PubMed Web of Science ®Google Scholar
• Dessein PH, Joffe BI, Veller MG, et al. Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol. 2005;32:435–442.
   PubMed Web of Science ®Google Scholar
• Corrales A, González-Juanatey C, Peiró ME, Blanco R, Llorca J, González-Gay MA. Carotid ultrasound is useful for the cardiovascular risk stratification of patients with rheumatoid arthritis: results of a population-based study. Ann Rheum Dis. 2014;73:722–727. doi:10.1136/annrheumdis-2012-203101
   PubMed Web of Science ®Google Scholar
• Eder L, Chandran V, Gladman DD. The Framingham Risk Score underestimates the extent of subclinical atherosclerosis in patients with psoriatic disease. Ann Rheum Dis. 2014;73:1990–1996. doi:10.1136/annrheumdis-2013-203433
   PubMed Web of Science ®Google Scholar
• Jamthikar A, Gupta D, Khanna NN, et al. A special report on changing trends in preventive stroke/cardiovascular risk assessment via B-mode ultrasonography. Curr Atheroscler Rep. 2019;21:25. doi:10.1007/s11883-019-0788-4
   PubMed Web of Science ®Google Scholar
• Jamthikar AD, Gupta D, Saba L, et al. Artificial intelligence framework for predictive cardiovascular and stroke risk assessment models: a narrative review of integrated approaches using carotid ultrasound. Comput Biol Med. 2020;126:104043. doi:10.1016/j.compbiomed.2020.104043
   PubMed Web of Science ®Google Scholar
• Weng SF, Reps J, Kai J, Garibaldi JM, Qureshi N. Can machine-learning improve cardiovascular risk prediction using routine clinical data? PLoS One. 2017;12:e0174944. doi:10.1371/journal.pone.0174944
   PubMed Web of Science ®Google Scholar
• Kakadiaris IA, Vrigkas M, Yen AA, Kuznetsova T, Budoff M, Naghavi M. Machine learning outperforms ACC/AHA CVD risk calculator in Mesa. J Am Heart Assoc. 2018;20:e009476. doi:10.1161/JAHA.118.009476
   Google Scholar
• Jamthikar A, Gupta D, Saba L, et al. Cardiovascular/stroke risk predictive calculators: a comparison between statistical and machine learning models. Cardiovasc Diagn Ther. 2020;10:919–938. doi:10.21037/cdt.2020.01.07
   PubMed Web of Science ®Google Scholar
• Fenton SAM, Duda JL, Veldhuijzen van Zanten JJ, Metsios GS, Kitas GD. Theory-informed interventions to promote physical activity and reduce sedentary behaviour in rheumatoid arthritis: a critical review of the literature. Mediterr J Rheumatol. 2020;31:19–41. doi:10.31138/mjr.31.1.19
   PubMedGoogle Scholar
• Sugiyama D, Nishimura K, Tamaki K, et al. Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis. 2010;69:70–81. doi:10.1136/ard.2008.096487
   PubMed Web of Science ®Google Scholar
• Crowson CS, Rollefstad S, Ikdahl E, et al. Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2018;77:48–54. doi:10.1136/annrheumdis-2017-211735
   PubMed Web of Science ®Google Scholar
• Santos MJ, Vinagre F, Canas da Silva J, Gil V, Fonseca JE. Body composition phenotypes in systemic lupus erythematosus and rheumatoid arthritis: a comparative study of Caucasian female patients. Clin Exp Rheumatol. 2011;29:470–476.
   PubMed Web of Science ®Google Scholar
• Markaki AG, Gkiouras K, Papakitsos C, et al. Disease activity, functional ability and nutritional status in patients with rheumatoid arthritis: an observational study in Greece. Mediterr J Rheumatol. 2020;31:406–411. doi:10.31138/mjr.31.4.406
   PubMedGoogle Scholar
• Hulander E, Bärebring L, Turesson Wadell A, et al. Diet intervention improves cardiovascular profile in patients with rheumatoid arthritis: results from the randomized controlled cross-over trial ADIRA. Nutr J. 2021;20:9. doi:10.1186/s12937-021-00663-y
   PubMed Web of Science ®Google Scholar
• Skoldstam L. An experimental study of a Mediterranean diet intervention for patients with rheumatoid arthritis. Ann Rheum Dis. 2003;62:208–214. doi:10.1136/ard.62.3.208
   PubMed Web of Science ®Google Scholar
• Dahan S, Segal Y, Shoenfeld Y. Dietary factors in rheumatic autoimmune diseases: a recipe for therapy? Nat Rev Rheumatol. 2017;13:348–358. doi:10.1038/nrrheum.2017.42
   PubMed Web of Science ®Google Scholar
• Fenton SAM, Veldhuijzen van Zanten JJ, Duda JL, Metsios GS, Kitas GD. Sedentary behaviour in rheumatoid arthritis: definition, measurement and implications for health. Rheumatology. 2018;57:213–226. doi:10.1093/rheumatology/kex053
   PubMed Web of Science ®Google Scholar
• O’Brien CM, Ntoumanis N, Duda JL, et al. Pain and fatigue are longitudinally and bi-directionally associated with more sedentary time and less standing time in rheumatoid arthritis. Rheumatology. 2021;25:keab029. doi:10.1093/rheumatology/keab029
   Google Scholar
• Metsios GS, Moe RH, Kitas GD. Exercise and inflammation. Best Pract Res Clin Rheumatol. 2020;34:101504. doi:10.1016/j.berh.2020.101504
   PubMed Web of Science ®Google Scholar
• Metsios GS, Stavropoulos-Kalinoglou A, Veldhuijzen van Zanten JJ, et al. Rheumatoid arthritis, cardiovascular disease and physical exercise: a systematic review. Rheumatology. 2008;47:239–248. doi:10.1093/rheumatology/kem260
   PubMed Web of Science ®Google Scholar
• Stavropoulos-Kalinoglou A, Metsios GS, Veldhuijzen van Zanten JJ, Nightingale P, Kitas GD, Koutedakis Y. Individualised aerobic and resistance exercise training improves cardiorespiratory fitness and reduces cardiovascular risk in patients with rheumatoid arthritis. Ann Rheum Dis. 2013;72:1819–1825. doi:10.1136/annrheumdis-2012-202075
   PubMed Web of Science ®Google Scholar
• Metsios GS, Moe RH, van der Esch M, et al. The effects of exercise on cardiovascular disease risk factors and cardiovascular physiology in rheumatoid arthritis. Rheumatol Int. 2020;4:347–357. doi:10.1007/s00296-019-04483-6
   Google Scholar
• Metsios GS, Stavropoulos-Kalinoglou A, Veldhuijzen van Zanten JJ, et al. Individualised exercise improves endothelial function in patients with rheumatoid arthritis. Ann Rheum Dis. 2014;73:748–751. doi:10.1136/annrheumdis-2013-203291
   PubMed Web of Science ®Google Scholar
• Metsios GS, Stavropoulos-Kalinoglou A, Kitas GD. The role of exercise in the management of rheumatoid arthritis. Expert Rev Clin Immunol. 2015;11:1121–1130. doi:10.1586/1744666X.2015.1067606
   PubMed Web of Science ®Google Scholar
• Anyfanti P, Gavriilaki E, Pyrpasopoulou A, et al. Depression, anxiety, and quality of life in a large cohort of patients with rheumatic diseases: common, yet undertreated. Clin Rheumatol. 2016;35:733–739. doi:10.1007/s10067-014-2677-0
   PubMed Web of Science ®Google Scholar
• Nikiphorou E, Santos EJF, Marques A, et al. 2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis. Ann Rheum Dis. 2021;80:1278–1285. doi:10.1136/annrheumdis-2021-220249
   PubMed Web of Science ®Google Scholar
• Tobias D. Risk of admission for CHF is higher for rofecoxib and nonselective NSAID users. Commentary: cyclo-oxygenase-2 inhibitors versus nonselective, nonsteroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Consult Pharm. 2004;19:1038–1042. doi:10.4140/tcp.n.2004.1038
   PubMedGoogle Scholar
• Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet (London, England). 2002;360:1071–1073. doi:10.1016/S0140-6736(02)11131-7
   PubMed Web of Science ®Google Scholar
• Hermann M, Ruschitzka F. Coxibs, non-steroidal anti-inflammatory drugs and cardiovascular risk. Intern Med J. 2006;36:308–319. doi:10.1111/j.1445-5994.2006.01056.x
   PubMed Web of Science ®Google Scholar
• Panoulas VF, Metsios GS, Pace AV, et al. Hypertension in rheumatoid arthritis. Rheumatology (Oxford, England). 2008;47:458. doi:10.1093/rheumatology/ken159
   PubMedGoogle Scholar
• Whelton A. Renal and related cardiovascular effects of conventional and COX-2-specific NSAIDs and non-NSAID analgesics. Am J Ther. 2000;7:63–74. doi:10.1097/00045391-200007020-00004
   PubMedGoogle Scholar
• Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342:c7086–c7086. doi:10.1136/bmj.c7086
   PubMed Web of Science ®Google Scholar
• Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med. 2016;375(26):2519–2529. doi:10.1056/NEJMoa1611593
   PubMed Web of Science ®Google Scholar
• Del Rincón I, Battafarano DF, Restrepo JF, Erikson JM, Escalante A. Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheumatol. 2014;66:264–272. doi:10.1002/art.38210
   PubMed Web of Science ®Google Scholar
• Ocon AJ, Reed G, Pappas DA, Curtis JR, Kremer JM. Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis. Ann Rheum Dis. 2021;80(12):1522–1529. doi:10.1136/annrheumdis-2021-220577
   PubMed Web of Science ®Google Scholar
• Roubille C, Coffy A, Rincheval N, et al. Ten-year analysis of the risk of severe outcomes related to low-dose glucocorticoids in early rheumatoid arthritis. Rheumatology (Oxford, England). 2021;60(8):3738–3746. doi:10.1093/rheumatology/keaa850
   PubMed Web of Science ®Google Scholar
• Mebrahtu TF, Morgan AW, West RM, Stewart PM, Pujades-Rodriguez M. Oral glucocorticoids and incidence of hypertension in people with chronic inflammatory diseases: a population-based cohort study. CMAJ. 2020;192:295–301. doi:10.1503/cmaj.191012
   PubMed Web of Science ®Google Scholar
• Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr Pract. 2009;15:469–474. doi:10.4158/EP08331.RAR
   PubMed Web of Science ®Google Scholar
• Gurwitz JH, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med. 1994;154:97–101. doi:10.1001/archinte.1994.00420010131015
   PubMedGoogle Scholar
• Ruyssen-Witrand A, Fautrel B, Saraux A, le Loët X, Pham T. Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review. Joint Bone Spine. 2011;78:23–30. doi:10.1016/j.jbspin.2010.02.040
   PubMed Web of Science ®Google Scholar
• Xie W, Yang X, Ji L, Zhang Z. Incident diabetes associated with hydroxychloroquine, methotrexate, biologics and glucocorticoids in rheumatoid arthritis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2020;50(4):598–607. doi:10.1016/j.semarthrit.2020.04.005
   PubMed Web of Science ®Google Scholar
• Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. 1997;145:408–415. doi:10.1093/oxfordjournals.aje.a009122
   PubMed Web of Science ®Google Scholar
• Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med. 1992;93:513–519. doi:10.1016/0002-9343(92)90578-Y
   PubMed Web of Science ®Google Scholar
• Doria A, Shoenfeld Y, Wu R, et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis. 2003;62:1071–1077. doi:10.1136/ard.62.11.1071
   PubMed Web of Science ®Google Scholar
• Micha R, Imamura F, Wyler von Ballmoos M, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol. 2011;108:1362–1370. doi:10.1016/j.amjcard.2011.06.054
   PubMed Web of Science ®Google Scholar
• Mangoni AA, Zinellu A, Sotgia S, Carru C, Erre GL. Methotrexate and cardiovascular protection: current evidence and future directions. Clin Med Insights Therap. 2017;9:1179559X17741289.
   Google Scholar
• Chan ESL, Cronstein BN. Methotrexate–how does it really work? Nat Rev Rheumatol. 2010;6:175–178. doi:10.1038/nrrheum.2010.5
   PubMed Web of Science ®Google Scholar
• Ganguly P, Alam SF. Role of homocysteine in the development of cardiovascular disease. Nutr J. 2015;14:1. doi:10.1186/1475-2891-14-6
   PubMed Web of Science ®Google Scholar
• van Ede AE, Laan RF, Blom HJ, et al. Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology. 2002;41:658–665. doi:10.1093/rheumatology/41.6.658
   PubMedGoogle Scholar
• Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Zaharris E. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med. 2019;380(8):752–762. doi:10.1056/NEJMoa1809798
   PubMed Web of Science ®Google Scholar
• Johnson TM, Sayles HR, Baker JF, George MD, Roul P, Zheng C. Investigating changes in disease activity as a mediator of cardiovascular risk reduction with methotrexate use in rheumatoid arthritis. Ann Rheum Dis. 2021;80(11):1385–1392. doi:10.1136/annrheumdis-2021-220125
   PubMed Web of Science ®Google Scholar
• Rempenault C, Combe B, Barnetche T, et al. Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2018;77:98–103. doi:10.1136/annrheumdis-2017-211836
   PubMed Web of Science ®Google Scholar
• Bili A, Sartorius JA, Kirchner HL, et al. Hydroxychloroquine use and decreased risk of diabetes in rheumatoid arthritis patients. J Clin Rheumatol. 2011;17:115–120. doi:10.1097/RHU.0b013e318214b6b5
   PubMed Web of Science ®Google Scholar
• Hage MP, Al-Badri MR, Azar ST. A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role. Ther Adv Endocrinol Metab. 2014;5:77–85. doi:10.1177/2042018814547204
   PubMedGoogle Scholar
• Solomon DH. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA. 2011;305:2525–2531. doi:10.1001/jama.2011.878
   PubMed Web of Science ®Google Scholar
• Robert N, Wong GW, Wright JM. Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev. 2010;1:CD007893. doi:10.1002/14651858.CD007893.pub2
   PubMed Web of Science ®Google Scholar
• Rozman B. Clinical experience with leflunomide in rheumatoid arthritis. Leflunomide Investigators’ Group. J Rheumatol. 1998;53:27–32.
   Google Scholar
• Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74:480–489. doi:10.1136/annrheumdis-2014-206624
   PubMed Web of Science ®Google Scholar
• Barnabe C, Martin B-J, Ghali WA. Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res. 2011;63:522–529. doi:10.1002/acr.20371
   PubMed Web of Science ®Google Scholar
• Sandoo A, Panoulas VF, Toms TE, et al. Anti-TNFα therapy may lead to blood pressure reductions through improved endothelium-dependent microvascular function in patients with rheumatoid arthritis. J Hum Hypertens. 2011;25:699–702. doi:10.1038/jhh.2011.36
   PubMed Web of Science ®Google Scholar
• Zhao Q, Hong D, Zhang Y, Sang Y, Yang Z, Zhang X. Association between anti-TNF therapy for rheumatoid arthritis and hypertension. Medicine. 2015;94:e731. doi:10.1097/MD.0000000000000731
   PubMed Web of Science ®Google Scholar
• Toms E, Symmons P, Kitas G. Dyslipidaemia in rheumatoid arthritis: the role of inflammation, drugs, lifestyle and genetic factors. Curr Vasc Pharmacol. 2010;8:301–326. doi:10.2174/157016110791112269
   PubMed Web of Science ®Google Scholar
• McInnes IB, Thompson L, Giles JT, et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis. 2015;74:694–702. doi:10.1136/annrheumdis-2013-204345
   PubMed Web of Science ®Google Scholar
• Chatzidionysiou K. Beyond methotrexate and biologics in RA – efficacy of JAK inhibitors and their place in the current treatment armamentarium. Mediterr J Rheumatol. 2020;31:120–128. doi:10.31138/mjr.31.1.120
   PubMedGoogle Scholar
• Taylor PC, Weinblatt ME, Burmester GR, et al. Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis. Arthritis Rheumatol. 2019;71:1042–1055. doi:10.1002/art.40841
   PubMed Web of Science ®Google Scholar
• FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death. Accessed November 23, 2021.
   Google Scholar
• Xie W, Xiao S, Huang Y, Sun X, Zhang Z. Effect of tofacitinib on cardiovascular events and all-cause mortality in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis of randomized controlled trials. Ther Adv Musculoskelet Dis. 2019;11:1759720X19895492. doi:10.1177/1759720X19895492
   PubMed Web of Science ®Google Scholar
• Xie W, Huang Y, Xiao S, Sun X, Fan Y, Zhang Z. Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis. 2019;78(8):1048–1054. doi:10.1136/annrheumdis-2018-214846
   PubMed Web of Science ®Google Scholar
• Moreira FRC, de Oliveira TA, Ramos NE, Abreu MAD, Simões E, Silva AC. The role of renin angiotensin system in the pathophysiology of rheumatoid arthritis. Mol Biol Rep. 2021;48:6619–6629. doi:10.1007/s11033-021-06672-8
   PubMed Web of Science ®Google Scholar
• Dandona P, Dhindsa S, Ghanim H and Chaudhuri A. Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. Journal of human hypertension. 21, 2007. doi:10.1038/sj.jhh.1002101.
   Google Scholar
• Kitas GD, Nightingale P, Armitage J, et al. A multicenter, randomized, placebo‐controlled trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheumatol. 2019;71:1437–1449. doi:10.1002/art.40892
   PubMed Web of Science ®Google Scholar
• Panoulas V, Kitas GD. Pharmacological management of cardiovascular risk in chronic inflammatory rheumatic diseases. Expert Rev Clin Pharmacol. 2020;13:605–613. doi:10.1080/17512433.2020.1766964
   PubMed Web of Science ®Google Scholar
• Solomon DH, Love TJ, Canning C, Schneeweiss S. Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis. Ann Rheum Dis. 2010;69:2114–2117. doi:10.1136/ard.2009.125476
   PubMed Web of Science ®Google Scholar
• Charlton R, Green A, Shaddick G, et al. Risk of type 2 diabetes and cardiovascular disease in an incident cohort of people with psoriatic arthritis: a population-based cohort study. Rheumatology. 2019;58:144–148. doi:10.1093/rheumatology/key286
   PubMed Web of Science ®Google Scholar
• Bruce IN, Urowitz MB, Gladman DD, Ibañez D, Steiner G. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum. 2003;48:3159–3167. doi:10.1002/art.11296
   PubMed Web of Science ®Google Scholar
• Chung CP, Oeser A, Solus JF, et al. Inflammation‐associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum. 2008;58:2105–2112. doi:10.1002/art.23600
   PubMed Web of Science ®Google Scholar
• Lillegraven S, Greenberg JD, Reed GW, et al. Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis. PLoS One. 2019;14:e0210459. doi:10.1371/journal.pone.0210459
   PubMed Web of Science ®Google Scholar
• Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:4317. doi:10.1093/eurheartj/ehz486
   PubMed Web of Science ®Google Scholar